Adenovirus as vector for HIV: efficacy and safety issues.
Natuk
R J
RJ
Wyeth-Ayerst Research, Biotechnology and Microbiology Division, Philadelphia, PA, USA.
Wade
M S
MS
Chengalvala
M
M
Murthy
K K
KK
Chanda
P K
PK
Murthy
S C
SC
Bhat
B M
BM
Bhat
R
R
Dheer
S K
SK
Mizutani
S
S
D016915:AIDS Vaccines / Q000009:adverse effects / Q000302:isolation & purification* / Q000592:standards; D000260:Adenoviruses, Human / Q000235:genetics / Q000276:immunology*; D000284:Administration, Oral; D000818:Animals; D005260:Female; D005822:Genetic Vectors; D015483:HIV Antibodies / Q000096:biosynthesis; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000502:physiology; D006801:Humans; D007115:Immunization Schedule; D002679:Pan troglodytes; D012449:Safety; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000302:isolation & purification* / Q000592:standards; D014779:Virus Replication
D016915:AIDS Vaccines; D015483:HIV Antibodies; D014614:Vaccines, Synthetic